Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Etoposide is named as an intervention in 94 current clinical trials in our China, USA, UK, Ireland and India registers. 56 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Chia Tai Tianqing Pharmaceutical Group Co., Ltd (5). The most-studied condition is Extensive-stage Small-cell Lung Cancer.

Trials by status

Recruiting5660%
Not yet open1415%
Active, closed2426%

Trials by phase

Phase 24346%
Phase 33133%
Phase 1/21112%
Phase 155%
Observational11%
Phase 411%
Phase 2/311%
Not applicable11%

Clinical trials of Etoposide

94 trials

Study	Phase	Status	Lead sponsor	Registers
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) NCT01704716 · Neuroblastoma	Phase 3	Recruiting	St. Anna Kinderkrebsforschung	Ireland
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors NCT02429687 · ClinicalTrials.gov ↗ · Ovarian Germ Cell Cancer, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Recruiting	Beihua Kong	China
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors NCT02429700 · ClinicalTrials.gov ↗ · Ovarian Sex Cord Stromal Tumor, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Recruiting	Beihua Kong	China
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors NCT03067181 · ClinicalTrials.gov ↗ · Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor	Phase 3	Recruiting	Children's Oncology Group	India
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) NCT04638790 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma, Adult	Phase 3	Recruiting	State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia	India
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma NCT06520163 · ClinicalTrials.gov ↗ · Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization	Phase 3	Recruiting	The Affiliated People's Hospital of Ningbo University	China
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients NCT06520176 · ClinicalTrials.gov ↗ · Multiple Myeloma, Hematopoietic Stem Cell Mobilization	Phase 3	Recruiting	The Affiliated People's Hospital of Ningbo University	China
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). NCT06646276 · Extensive-Stage Small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer NCT06712355 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 3	Recruiting	BioNTech SE	UK, USA, China
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06792253 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	BeBetter Med Inc	China
Omitting CTV for Primary Tumor in LS-SCLC NCT07008716 · ClinicalTrials.gov ↗ · SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect	Phase 3	Recruiting	Sun Yat-sen University	China
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy NCT07472517 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 3	Recruiting	Boehringer Ingelheim	Ireland, UK, USA, China
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) NCT07502300 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy NCT07544654 · ClinicalTrials.gov ↗ · Extrapulmonary Neuroendocrine Cancer (epNEC)	Phase 3	Recruiting	Boehringer Ingelheim	UK, USA, China
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) NCT07625644 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma	Phase 3	Recruiting	SystImmune Inc.	USA
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer NCT07739758 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 3	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	China
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment NCT06563245 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma, Child, Adolescent	Phase 2/3	Recruiting	Children's Cancer Group, China	China
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer NCT04539977 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients NCT05252078 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Esophageal Diseases	Phase 2	Recruiting	Jiangxi Provincial Cancer Hospital	China
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma NCT05294055 · ClinicalTrials.gov ↗ · Multiple Myeloma, Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer NCT05913089 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma NCT06091124 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinoma of the Bladder, Bladder Cancer	Phase 2	Recruiting	RenJi Hospital	China
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC NCT06125041 · ClinicalTrials.gov ↗ · Extensive Small Cell Lung Cancer	Phase 2	Recruiting	Qianfoshan Hospital	China
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma NCT06140966 · ClinicalTrials.gov ↗ · Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer NCT06141226 · ClinicalTrials.gov ↗ · Non-small-cell Lung Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC NCT06177925 · ClinicalTrials.gov ↗ · Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site	Phase 2	Recruiting	Nanfang Hospital, Southern Medical University	China
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML NCT06221683 · ClinicalTrials.gov ↗ · AML, Childhood, Acute Myeloid Leukemia	Phase 2	Recruiting	Children's Hospital of Soochow University	China
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON) NCT06255210 · ClinicalTrials.gov ↗ · Olfactory Neuroblastoma	Phase 2	Recruiting	Hongmeng Yu	China
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer NCT06483282 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Limited Stage	Phase 2	Recruiting	Jin Ying	China
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial NCT06485544 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC)	Phase 2	Recruiting	Tang-Du Hospital	China
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality NCT06496490 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	China
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC NCT06497530 · ClinicalTrials.gov ↗ · Extensive-Stage Small Cell Lung Cancer	Phase 2	Recruiting	Guangzhou Institute of Respiratory Disease	China
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma NCT06528847 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC NCT06637163 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Shanghai Zhongshan Hospital	China
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) NCT06733051 · ClinicalTrials.gov ↗ · Natural Killer T-cell Lymphoma	Phase 2	Recruiting	Sun Yat-sen University	China
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma NCT06767800 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	China
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC NCT06769971 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	Sichuan University	China
Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases NCT06953843 · ClinicalTrials.gov ↗ · NSCLC Stage IV Without EGFR/ALK Mutation	Phase 2	Recruiting	Xinqiao Hospital of Chongqing	China
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy NCT06992336 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy NCT07141264 · ClinicalTrials.gov ↗ · SCLC,Extensive Stage	Phase 2	Recruiting	Tang-Du Hospital	China
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer NCT07155174 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	AbbVie	USA, China
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors NCT07268040 · ClinicalTrials.gov ↗ · Malignant Solid Tumors	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma NCT07548177 · ClinicalTrials.gov ↗ · Alveolar Soft Part Sarcoma	Phase 2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement NCT04432714 · ClinicalTrials.gov ↗ · DLBCL, Untreated, MYC Gene Rearrangement	Phase 1/2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma NCT05533775 · ClinicalTrials.gov ↗ · Mature B-Cell Non-Hodgkin Lymphoma	Phase 1/2	Recruiting	Hoffmann-La Roche	USA, China
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) NCT05652686 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
IN10018 Combination Therapy in Treatment-naïve ES-SCLC NCT06030258 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 1/2	Recruiting	InxMed (Shanghai) Co., Ltd.	China
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC NCT06217757 · ClinicalTrials.gov ↗ · Lung Cancer, Extensive-stage Small-cell Lung Cancer	Phase 1/2	Recruiting	Sichuan University	China
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC NCT07136285 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 1/2	Recruiting	Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.	China
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) NCT07227597 · Small Cell Lung Cancer Extensive Stage	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) NCT07525466 · ClinicalTrials.gov ↗ · Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH)	Phase 1/2	Recruiting	Beijing Tongren Hospital	China
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer NCT07381829 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer	Phase 1	Recruiting	HC Biopharma Inc.	China
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy NCT06869239 · ClinicalTrials.gov ↗ · Limited-stage Small Cell Lung Cancer (LS-SCLC)	Observational	Recruiting	Peking University Cancer Hospital & Institute	China
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH NCT05936086 · ClinicalTrials.gov ↗ · Hemophagocytic Syndrome	Not applicable	Recruiting	shifeng Lou	China
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer NCT06931145 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer	Phase 4	Not yet open	Peking Union Medical College Hospital	China
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients NCT06469879 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Limited Stage	Phase 3	Not yet open	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer NCT06475599 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 3	Not yet open	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China
A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT07446335 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma	Phase 3	Not yet open	The First Affiliated Hospital of Zhengzhou University	China
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC NCT07720193 · ClinicalTrials.gov ↗ · Advanced Extrapulmonary Neuroendocrine Carcinoma	Phase 3	Not yet open	Nanjing Leads Biolabs Co.,Ltd	China
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer NCT06109402 · ClinicalTrials.gov ↗ · Stage II-IIIB(N2) Non-small Cell Lung Cancer	Phase 2	Not yet open	Shanghai Pulmonary Hospital, Shanghai, China	China
Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) NCT06621095 · ClinicalTrials.gov ↗ · Pancreatic Cancer, First-line, Metastatic Pancreatic Cancer	Phase 2	Not yet open	RenJi Hospital	China
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC NCT06699498 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer NCT06786312 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 2	Not yet open	Fujian Cancer Hospital	China
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033 NCT07097948 · ClinicalTrials.gov ↗ · Postoperative Incidental Small Cell Lung Cancer, Toripalimab Adjuvant Therapy Evaluation	Phase 2	Not yet open	Shanghai Pulmonary Hospital, Shanghai, China	China
A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC NCT07510594 · ClinicalTrials.gov ↗ · Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy NCT07627464 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma (RCC)	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC NCT07643350 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Not yet open	The Third Xiangya Hospital of Central South University	China
GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma NCT07768943 · ClinicalTrials.gov ↗ · Natural Killer/T-cell Lymphoma	Phase 2	Not yet open	Fudan University	China
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors NCT02375204 · ClinicalTrials.gov ↗ · Germ Cell Tumor, Teratoma, Choriocarcinoma	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Ireland
Paediatric Hepatic International Tumour Trial NCT03017326 · ClinicalTrials.gov ↗ · Hepatoblastoma, Carcinoma, Hepatocellular	Phase 3	Active, closed	University of Birmingham	Ireland
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) NCT03043872 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma Extensive Disease	Phase 3	Active, closed	AstraZeneca	USA, China
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636 · ClinicalTrials.gov ↗ · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer NCT04523272 · ClinicalTrials.gov ↗ · Advanced Renal Cancer	Phase 3	Active, closed	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer NCT05091567 · Small-Cell Lung Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) NCT05224141 · Small Cell Lung Carcinoma	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer NCT05566041 · ClinicalTrials.gov ↗ · Carcinoma, Small Cell Lung	Phase 3	Active, closed	EpicentRx, Inc.	USA
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma NCT05605899 · High-risk Large B-cell Lymphoma (LBCL)	Phase 3	Active, closed	Kite, A Gilead Company	UK, USA
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features NCT06564844 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer	Phase 3	Active, closed	Amgen	USA, China
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) NCT03407144 · Hodgkin Lymphoma	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) NCT03944772 · Non-Small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA
Study of AZD2811 + Durvalumab in ES-SCLC NCT04745689 · ClinicalTrials.gov ↗ · Small-Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC NCT05765825 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Active, closed	Sichuan University	China
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC NCT05844150 · ClinicalTrials.gov ↗ · SCLC	Phase 2	Active, closed	Biotheus Inc.	China
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy NCT06449209 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer	Phase 2	Active, closed	BioNTech SE	UK, USA
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression NCT06939452 · ClinicalTrials.gov ↗ · Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	Phase 2	Active, closed	Yongxu Jia	China
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC NCT06477523 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 1/2	Active, closed	Sichuan University	China
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) NCT05361395 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer	Phase 1	Active, closed	Amgen	USA
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC NCT05595460 · ClinicalTrials.gov ↗ · SCLC,Extensive Stage	Phase 1	Active, closed	RayzeBio, Inc.	USA
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer NCT06077500 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma (SCLC)	Phase 1	Active, closed	Boehringer Ingelheim	USA
A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer NCT07009457 · ClinicalTrials.gov ↗ · Widespread Small Cell Lung Cancer	Phase 1	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Etoposide across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

5 single-substance products containing Etoposide on the HPRA medicines list.

Etoposide 20 mg/ml Concentrate for Solution for InfusionAccord Healthcare Ireland Ltd. · PA2315/201/001 · Marketed
Etoposide 20 mg/ml concentrate for solution for infusionFresenius Kabi Deutschland GmbH · PA2059/036/001 · Marketed
Etoposide-Teva 20 mg/ml Concentrate for Solution for InfusionTeva Pharma B.V. · PA0749/002/001 · Marketed
VEPESID 100 mg capsule, softCHEPLAPHARM Arzneimittel GmbH · PA2239/006/002 · Marketed
VEPESID 50 mg capsule, softCHEPLAPHARM Arzneimittel GmbH · PA2239/006/001 · Marketed

All 5 Irish products →

Supply shortages

No entry for Etoposide in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Etoposide

119 conditions

Extensive-stage Small-cell Lung Cancer5 Small-cell Lung Cancer4 Small Cell Lung Cancer Extensive Stage4 Small Cell Lung Cancer (SCLC)3 Non-Small Cell Lung Cancer3 SCLC, Extensive Stage3 Multiple Myeloma3 Extensive-Stage Small Cell Lung Cancer2 Small-Cell Lung Cancer2 SCLC,Extensive Stage2 Small Cell Lung Cancer2Germ Cell Tumor2

All 119 conditions

Condition (as registered)	Trials
Extensive-stage Small-cell Lung Cancer	5
Small-cell Lung Cancer	4
Small Cell Lung Cancer Extensive Stage	4
Small Cell Lung Cancer (SCLC)	3
Non-Small Cell Lung Cancer	3
SCLC, Extensive Stage	3
Multiple Myeloma	3
Extensive-Stage Small Cell Lung Cancer	2
Small-Cell Lung Cancer	2
SCLC,Extensive Stage	2
Small Cell Lung Cancer	2
Germ Cell Tumor	2
Ovarian Neoplasms	2
Ovarian Cancer	2
Small Cell Lung Cancer Limited Stage	2
Hematopoietic Stem Cell Mobilization	2
Esophageal Squamous Cell Carcinoma	2
Breast Cancer	2
Neuroblastoma	1
Small Cell Lung Carcinoma	1
Hepatoblastoma	1
Carcinoma, Hepatocellular	1
Extensive-stage Small Cell Lung Cancer (ES-SCLC)	1
Hodgkin Lymphoma	1
High-risk Large B-cell Lymphoma (LBCL)	1
Extrapulmonary Neuroendocrine Cancer (epNEC)	1
Lung Neoplasms	1
Carcinoma, Non-Small-Cell Lung	1
Extensive Stage Small-cell Lung Cancer	1
Small Cell Lung Carcinoma (SCLC)	1
Mature B-Cell Non-Hodgkin Lymphoma	1
Advanced Solid Tumors	1
Small Cell Lung Carcinoma Extensive Disease	1
Small Cell Carcinoma	1
Sclc	1
Large Cell Neuroendocrine Cancer (LCNEC)	1
Neuroendocrine Prostate Cancer (NEPC)	1
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)	1
Extensive Stage Small Cell Lung Cancer	1
Non-small Cell Lung Cancer	1
Carcinoma, Small Cell Lung	1
Hodgkin Lymphoma, Adult	1
Childhood Extracranial Germ Cell Tumor	1
Extragonadal Embryonal Carcinoma	1
Malignant Germ Cell Tumor	1
Advanced Solid Tumor Cancer	1
Relapsed/Refractory Diffuse Large B-Cell Lymphoma	1
Limited-stage Small Cell Lung Cancer (LS-SCLC)	1
Primary Plasma Cell Leukemia	1
Extramedullary Multiple Myeloma	1
Respiratory Tract Neoplasms	1
Thoracic Neoplasms	1
Neoplasms by Site	1
Neoplasms	1
Neuroendocrine Carcinoma of the Bladder	1
Bladder Cancer	1
SCLC, Limited Stage	1
Radiation Exposure	1
Radiotherapy Side Effect	1
Progression	1
Extensive-stage Small Cell Lung Cancer	1
Ovarian Germ Cell Cancer	1
Ovarian Sex Cord Stromal Tumor	1
Postoperative Incidental Small Cell Lung Cancer	1
Toripalimab Adjuvant Therapy Evaluation	1
Malignant Solid Tumors	1
Extranodal NK T Cell Lymphoma	1
Hemophagocytic Lymphohistiocytosis (HLH)	1
Classical Hodgkin Lymphoma	1
Child	1
Adolescent	1
Young Adult	1
DLBCL	1
Untreated	1
MYC Gene Rearrangement	1
Olfactory Neuroblastoma	1
Large-Cell Neuroendocrine Carcinoma of the Lung	1
Extrapulmonary Neuroendocrine Carcinoma	1
SCLC	1
Widespread Small Cell Lung Cancer	1
Natural Killer/T-cell Lymphoma	1
Lymphoma	1
Lung Cancer	1
Hemophagocytic Syndrome	1
Extensive Small Cell Lung Cancer	1
Solid Cancer	1
AML, Childhood	1
Acute Myeloid Leukemia	1
Advanced Extrapulmonary Neuroendocrine Carcinoma	1
Non-Hodgkin's Lymphoma	1
Teratoma	1
Choriocarcinoma	1
Germinoma	1
Head and Neck Squamous Cell Carcinoma	1
Neoadjuvant Therapy	1
PD-L1	1
Anlotinib	1
Advanced Esophageal Squamous Cell Carcinoma	1
Renal Cell Carcinoma (RCC)	1
NSCLC Stage IV Without EGFR/ALK Mutation	1
Gastroesophageal Adenocarcinoma	1
Natural Killer T-cell Lymphoma	1
NSCLC	1
Pancreatic Cancer	1
First-line	1
Metastatic Pancreatic Cancer	1
Breast Neoplasm	1
Breast Tumors	1
Triple-Negative Breast Cancer (TNBC)	1
Alveolar Soft Part Sarcoma	1
Advanced Renal Cancer	1
Esophageal Neoplasms	1
Esophageal Diseases	1
Gastrointestinal Neoplasms	1
Stage II-IIIB(N2) Non-small Cell Lung Cancer	1
Non Small Cell Lung Cancer	1
Non-small-cell Lung Cancer	1
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	1
Endometrial Cancer	1

By country register

Register	Trials	Recruiting
Clinical trials in China	76	51
Clinical trials in USA	25	10
Clinical trials in UK	10	4
Clinical trials in Ireland	5	2
Clinical trials in India	3	3

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Etoposide trials

How many clinical trials are testing Etoposide?

94 current trials in our China, USA, UK, Ireland and India registers name Etoposide (also registered as VP16) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Etoposide trials recruiting patients?

Yes. 56 of the 94 trials are recruiting: 51 with sites in China, 10 with sites in USA, 4 with sites in UK, 2 with sites in Ireland and 3 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Etoposide clinical trials?

Chia Tai Tianqing Pharmaceutical Group Co., Ltd (5), Merck Sharp & Dohme LLC (4), AstraZeneca (4) and Sichuan University (4), among 63 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Etoposide licensed in Ireland?

Yes. The HPRA medicines list includes 5 single-substance products containing Etoposide, for example Etoposide 20 mg/ml Concentrate for Solution for Infusion (Accord Healthcare Ireland Ltd.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Etoposide shortage?

Not in the lists we track: Etoposide has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Etoposide works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Etoposide works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Etoposide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Etoposide clinical trials